Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Lexicon Pharmaceuticals, Inc.    LXRX

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 92,3 M
EBIT 2017 -163 M
Net income 2017 -156 M
Finance 2017 8,75 M
Yield 2017 -
Sales 2018 160 M
EBIT 2018 -58,5 M
Net income 2018 -98,9 M
Finance 2018 2,00 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 16,3x
EV / Sales2018 9,49x
Capitalization 1 516 M
More Financials
Company
Lexicon Pharmaceuticals, Inc. operates as a biopharmaceutical company which focuses on the development of breakthrough treatments for human disease.It has multiple programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications.The company was... 
More about the company
Surperformance© ratings of Lexicon Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on LEXICON PHARMACEUTICALS, I
05/18 LEXICON PHARMACEUTICALS : Reports Additional Positive Data From Pivotal InTandem..
05/11 LEXICON PHARMACEUTICALS : Reports First Quarter 2017 Financial Results And Provi..
05/10 LEXICON PHARMACEUTICALS : Catalent Provides Commercial Manufacturing of Lexicon ..
05/09 CATALENT : Provides Commercial Manufacturing of Lexicon Pharmaceuticals' Orphan ..
05/04 LEXICON PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
05/03 LEXICON PHARMACEUTICALS : reports 1Q loss
05/02 LEXICON PHARMACEUTICALS, INC. (NASDA : LXRX) Files An 8-K Results of Operations ..
05/02 LEXICON PHARMACEUTICALS, INC. : Results of Operations and Financial Condition (f..
04/27 LEXICON PHARMACEUTICALS, INC. (NASDA : LXRX) Files An 8-K Entry into a Material ..
04/27 LEXICON PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement (form..
More news
Sector news : Bio Therapeutic Drugs
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
2015 SEEKING ALPHA'S BIOTECH WEEKLY : A Gilead Victory, Celladon Crumbles, And More
2015 Lexicon Undervalued As It Approaches A Major Event
2015 Lexicon Pharmaceuticals' (LXRX) CEO Lonnel Coats on Q1 2015 Results - Earning..
2015 Lexicon Pharmaceuticals EPS in-line, beats on revenue
2015 Lexicon Pharmaceuticals - A Diamond In The Rough?
Advertisement
Chart LEXICON PHARMACEUTICALS, I
Duration : Period :
Lexicon Pharmaceuticals, I Technical Analysis Chart | LXRX | US5288721047 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 26,7 $
Spread / Average Target 85%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Lonnel Coats President, Chief Executive Officer & Director
Raymond Debbane Chairman
Jeffrey L. Wade CFO, EVP-Corporate & Administrative Affairs
Pablo Lapuerta Chief Medical Officer & EVP-Clinical Development
Frank P. Palantoni Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
LEXICON PHARMACEUTICAL..12.10%1 516
AMGEN, INC.6.02%113 994
CELGENE CORPORATION0.89%91 185
GILEAD SCIENCES, INC.-9.93%84 284
REGENERON PHARMACEUTIC..23.99%48 380
ACTELION LTD24.38%30 602
More Results